Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/QuidelOrtho Corporation/ 4

SEC Filing · 4

QuidelOrtho Corporation

QDELNASDAQEQUITYCurrent

SEC Filing

Filed Jul 2, 2026Accepted Jul 2, 2026, 4:06 PM EDTCIK 1906324Accession 0002123618-26-000009
View company →Permanent SEC source ↗
Share

Company context

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes - from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Current securities

QDELNASDAQ · EQUITY · Current

Recent company filings

  1. Entry into a Material Definitive AgreementSep 23, 2026
  2. 4 filingAug 18, 2026
  3. 10-Q filingAug 7, 2026
  4. Results of Operations and Financial ConditionAug 6, 2026
  5. 4 filingJul 16, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗